Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients

Movement Disorders

Volumn 24, Issue 2, 2009, Pages 176-182

  Camicioli, Richard M ^a,b   Bouchard, Thomas P ^a   Somerville, Martin J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

B vitamins; Homocysteine; Mental status; MTHFR; Parkinson's disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE; CYANOCOBALAMIN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; PYRIDOXINE;

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMENTIA; DYSKINESIA; ELDERLY CARE; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; RISK ASSESSMENT; VITAMIN INTAKE;

AGED; ANTIPARKINSON AGENTS; COGNITION; CREATININE; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METABOLIC DETOXICATION, DRUG; METHYLATION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; VITAMIN B COMPLEX;

EID: 61649100790     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22227     Document Type: Article

References (38)

1. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
2. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-891.
3. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004;19: 1403-1408.
4. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60: 1125-1129.
5. Shoulson I, Oakes D, Fahn S, et al. Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
6. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-2022.
7. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
8. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868.
9. Irizarry MC, Gurol ME, Raju S, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 2005;65:1402-1408.
10. Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005;43:1107-1110.
11. Zoccolella S, Lamberti P, Iliceto G, et al. Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med 2006;44:863-866.
12. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
14. Brown GG, Rahill AA, Gorell JM, et al. Validity of the dementia rating scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999;12:180-188.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988;24:709-711.
17. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140:734-739.
18. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
19. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-137.
20. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
21. Gancher ST. Scales for the assessment of movement disorders. In: Herndon RM, editor. Handbook of neurologic rating scales. New York: Demos Vermande; 1997. p 81-106.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
23. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
24. Louis M, Dekairelle AF, Gala JL. Rapid combined genotyping of factor V, prothrombin and methylenetetrahydrofolate reductase single nucleotide polymorphisms using minor groove binding DNA oligonucleotides (MGB probes) and real-time polymerase chain reaction. Clin Chem Lab Med 2004;42:1364-1369.
25. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006;404:56-60.
26. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopatreated patients with PD. Neurology 2000;55:437-440.
27. Todorovic Z, Dzoljic E, Novakovic I, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006; 248:56-61.
28. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease. J Neural Transm Suppl 2004:15-20.
29. Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006;29:106-111.
30. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intimamedia thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29:305-311.
31. Lutsep HL, Campbell S, Chambless LE, Howard VJ, Toole JF. Plasma total homocysteine levels in stroke patients screened for the vitamin intervention for stroke prevention clinical trial in the era of folate fortification. Neuroepidemiology 2006;26:45-51.
32. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005;26:361-371.
33. Agnati LF, Ferre S, Genedani S, et al. Allosteric modulation of dopamine D2 receptors by homocysteine. J Proteome Res 2006; 5:3077-3083.
34. Gerfen CR. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist 2003;9:455-462.
35. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006;354:2764-2772.
36. Durga J, van Boxtel MPJ, Schouten EG et al. Effect of 3-year folic acid supplementation on cogntive function in older adults in the FACIT trial: a randomized, double blind, controlled trial. Lancet 2007;369:208-216.
37. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006;354:1629-1632.
38. O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB, Jr, Bottiglieri T, Diaz-Arrastia R. Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord 2006;12:103-107.